Skip to main content
Premium Trial:

Request an Annual Quote

Inverness Terminates Thermo Fisher Contract to Resell Biosite Products

Premium

This story originally ran on Nov. 12.

Inverness Medical Innovations has terminated its contract with Thermo Fisher Scientific for the resale of Inverness' Biosite products.

The disclosure was made this week in a document filed by Thermo Fisher with the US Securities and Exchange Commission. The termination takes effect on July 1, 2010.

Inverness purchased Biosite in 2007. Among the products offered by Biosite are protein biomarker-based tests for congestive heart failure and cardiovascular diseases.

In its SEC filing, Thermo Fisher said that it believes Inverness terminated the contract and decided to sell directly to customers because of Thermo Fisher's recent decision to expand its diagnostic product offerings. Last month it announced it had completed its acquisition of German diagnostics firm BRAHMS for $471 million.

Later in October, it launched its copeptin assay for the diagnosis of acute myocardial infarction. The assay was developed by BRAHMS.

For 2009, Thermo Fisher expects $200 million in revenue from the sale of Biosite products. Because of the termination of the contract, that figure is anticipated to be cut by more than half in 2010, the company said. Sales of Biosite products are expected to be "minimal" in 2011 and beyond.

Thermo Fisher said that it has signed an agreement with another unnamed supplier of diagnostic products and expects $40 million in sales resulting from the agreement, offsetting a portion of the drop in Biosite sales.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.